Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Thomas Jefferson University Apollo Health Systems |
---|---|
Information provided by: | Thomas Jefferson University |
ClinicalTrials.gov Identifier: | NCT00269633 |
The specific aim of this study is to test the hypothesis that light stimuli concentrated around 468 nm will evoke a significantly stronger therapeutic response in SAD patients compared to light stimuli concentrated around 654 nm at an equal photon density.
The secondary objective of this study is to determine the efficacy of different colors and levels of light in order to optimize therapeutic benefit, while also minimizing side effects and maintaining safety of light exposure.
Condition | Intervention | Phase |
---|---|---|
Seasonal Affective Disorder |
Device: Light Box |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety Study |
Official Title: | Optimizing Light Wavelength for Treatment of Seasonal Affective Disorder |
Estimated Enrollment: | 30 |
Study Start Date: | November 2006 |
Estimated Study Completion Date: | November 2006 |
Studies report as many as 1 out of every 5 Americans is affected by mild to severe Seasonal Affective Disorder (SAD, winter depression). Although the exact cause of this condition is unknown, bright light has proven to be an effective therapeutic treatment for many people with SAD. The light sources that have been traditionally used for treatment of SAD produce white light with great variability in the balance of wavelengths that are emitted across the visible spectrum. Although several studies have attempted to test the effectiveness of different wavelengths for treatment of SAD, the devices used in those studies employed broad bandwidths of light. With the technological advancements in light emitting diodes (LEDs) the production of new light therapy equipment with much narrower bandwidths of light is possible. Side effects of exposure to traditional white light therapy for SAD have included hypomanic activation, irritability, headache, eyestrain and nausea. We hypothesize that when the wavelength of light therapy is optimized, it should be feasible to elicit strong therapeutic benefits with lower light intensities and fewer side effects. Previous studies, approved by the Jefferson IRB and successfully completed by our laboratory have shown that some colors of light are more effective in treating SAD than other colors.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Kathleen E West, B.S. | 215-955-9409 | kathleen.west@jefferson.edu |
Contact: John P Hanifin, B.A. | 215-955-9409 | john.hanifin@jefferson.edu |
United States, Pennsylvania | |
Thomas Jefferson University | Recruiting |
Philadelphia, Pennsylvania, United States, 19107 | |
Contact: Kathleen E West, B.S. 215-955-9409 kathleen.west@jefferson.edu | |
Principal Investigator: George C Brainard, Ph.D. | |
Sub-Investigator: Brenda Byrne, Ph.D. |
Principal Investigator: | George C Brainard, Ph.D. | Thomas Jefferson University |
Study ID Numbers: | 080-19000-J11401 |
Study First Received: | December 22, 2005 |
Last Updated: | November 6, 2006 |
ClinicalTrials.gov Identifier: | NCT00269633 |
Health Authority: | United States: Institutional Review Board |
Seasonal Affective Disorder |
Seasonal Affective Disorder Depression Mental Disorders Mood Disorders Depressive Disorder |
Pathologic Processes Disease |